Metformin is a commonly used medication in diabetic patients. It can cause different complications including cutaneous adverse reactions. Metformin-induced fixed-drug eruption (FDE) has been reported in limited cases. Due to the popularity of metformin, clinicians need to be aware of uncommon drug reactions for proper diagnosis and treatment. Herein, we report a 43-year-old man with generalized bullous lesions with a positive dechallenge-rechallenge test diagnosed as metformin-induced generalized bullous fixed-drug eruption. Metformin dosage was stopped and lesions were treated with topical clobetasol propionate and oral prednisolone and cyclosporine-A. After a 6-month follow-up, he was well without any relapsing episodes.
Background: Seborrheic keratosis is a benign epidermal proliferation, which is highly common in sun-exposed areas. This study evaluated the clinicopathological characteristics of seborrheic keratosis lesions in patients referred to the Afzalipour Hospital, Kerman, Iran. Methods: This retrospective cross-sectional study investigated ninety-nine skin biopsies of seborrheic keratosis lesions. The patients’ demographic features and the clinical and pathological features of the lesions were recorded. Then the correlation between pathological subtypes and demographics and clinical features was evaluated. Independent t-test and chi-square tests were used to assess the correlation between quantitative and qualitative data, respectively. Results: A majority of the patients were female (56.6%) in the sixth decade of their lives (33.3%). The lesions were more frequent in sun-exposed areas (65.6%). The most common pathological subtypes were acanthotic (47.5%), hyperkeratotic (27.3%), and adenoid (14.1%), and horn cyst (75.8%) and squamous eddies (5.1%) were the most and the least prevalent pathological features, respectively. Moreover, no significant correlation was noticed between pathological subtypes with the patients’ age or sun-exposed areas (P = 0.257 & P = 0.05, respectively) Conclusions: The most common pathological subtype in this study was the acanthotic type. There was no correlation between pathological subtypes and the patients’ demographic features. The most common clinicopathological correlation was associated with the sun-protected lesions.
1 May 2016 in Journal of Investigative Dermatology
, Iran (the Islamic Republic of) Dystrophic epidermolysis bullosa (DEB) is caused by mutations in the COL7A1 gene. The knowledge of specific mutations is a prerequisite for prenatal testing and preimplantation genetic diagnosis as well as for application of allele-specific therapies. In this study, we examined a cohort of 147 DEB Iranian families consisting of 215 affected individuals. Among these families 133 were consanguineous (>90%), with the parents of the probands being first or second cousins. The diagnosis of DEB was based on clinical observations and immunofluorescence staining. First, 65 families were analized by traditional Sanger sequencing of all 118 exons and flanking intronic sequences of COL7A1. Secondly, a gene-targeted next generation sequencing (NGS) panel was constructed covering the entire gene and was used for analysis of 82 additional families. Targeted sequencing of COL7A1 was performed on the IonTorrent PGM, using an AmpliSeq 3-pool primer design designed to capture all COL7A1 exons plus 50-bp flanking regions; this approach also verified the mutations discovered in a subset of patients by Sanger sequencing. A total of 95 unique mutations were identified, 48 of them by Sanger sequencing and 47 by NGS; among the 95 mutations, 27 were missense, 33 indel, 10 splice junction, and 25 premature termination codon-causing mutations. A recurrent c.6269_6270delC (p.Pro2090LeufsX116) was found in 14 families. Haplotype analysis of the COL7A1 locus on chromosomal region 3p21.1 identified a w4.6 Mb conserved homozygosity block flanking COL7A1 gene, indicating a founder effect. NGS approach allows expedient analysis of a large number of samples, the cost being w1/3 of that of Sanger sequencing. Our data also emphasize the need for population-specific diagnostic and management approaches for EB.
1 September 2016 in Journal of Investigative Dermatology